RxDoctor Payments Data

Syed Ahmed, MD

Sleep Medicine · Germantown, MDNPI 1144434887

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $57,196 of the $75,431 with a category attached, or 75.8%. 55 manufacturers reported payments, led by AbbVie at 58.5% of the total. Among sleep medicine clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$75,431in general payments, 2019–2025

Across 1,054 payments — averaging $71.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$44K
  • Jazz Pharmaceuticals Inc.$7K
  • Biohaven Pharmaceuticals, Inc.$7K
  • Biohaven Pharmaceutical Holding Company Ltd.$5K
  • Inspire Medical Systems, Inc.$2K
  • Lilly USA, LLC$1K
  • plus $9K from 49 others

What the payments were for

  • Speaking & faculty fees$57,19676%
  • Travel & lodging$6951%
  • Food & beverage$17,42723%
  • Education$1120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$75,431 in reported general payments places this provider in the 95th percentile of 41 sleep medicine providers in Maryland.

See all sleep medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$378,247
Medicare patients
774
Services billed
8,651

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VumerityDiroximel Fumarate12$80,108
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5024$62,640
BotoxOnabotulinumtoxina14$23,098
RytaryCarbidopa/Levodopa14$20,284
Nurtec OdtRimegepant Sulfate11$16,224
Memantine Hcl185$7,374
Rasagiline Mesylate20$3,483
Memantine Hcl ErMemantine Hcl21$3,412
Carbidopa-LevodopaCarbidopa/Levodopa102$2,251
Levetiracetam31$1,820
Gabapentin95$1,587
Propranolol Hcl ErPropranolol Hcl35$1,563
Primidone42$1,403
Donepezil Hcl89$1,342
AmantadineAmantadine Hcl18$1,313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenVumerity$590$80,10812 claims
AbbVieBotox$44,115$23,09814 claims
Amneal Pharmaceuticals LLCRytary$353$20,28414 claims
PfizerNurtec Odt$1,001$16,22411 claims
Upsher-smith Laboratories LLCTopiramate$131$23711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 41 sleep medicine providers in Maryland.

Other sleep medicine in Germantown

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →